Eisai establishes a European strategic business hub in the U.K.
Eisai Europe Ltd. , a regional headquarter in Europe and a subsidiary of Eisai Co., Ltd. concluded the Heads of Terms with Arlington Securities Ltd. in the U.K. on land sales and the development to establish a strategic business hub in Europe. Eisai will consolidate the internal functions including discovery research, clinical development, production, sales and headquarters operations in Europe in this place to establish a strategic business hub which will be a center of business activities across Europe.
The site Eisai concluded the Heads of Terms this time is about 14.6 acres of land in the Hatfield Business Park located in the northern London and a new manufacturing subsidiary with plants will be built here. The construction will be started in 2006 and Eisai Europe Ltd., an existing regional headquarter in Europe, and Eisai Ltd., a subsidiary of clinical research and sales, will be sequentially relocated to this site. Further adding a discovery research function to the site to expand and strengthen Eisai London Research Laboratories, Ltd., a subsidiary of discovery research located at the University of London (UCL), the first production and research activities for drug discovery will be started in 2008. Eisai assumes that total invested amount including cost for purchasing the land will be approx. 15 billion yen. Furthermore, establishment of the hub will create more than 500 jobs in total including new employment of 300 employees in the Hatfield Business Park.
Eisai has already set up sales subsidiaries in major regions of Europe including the U.K., Germany, France, Spain, Italy, Switzerland and Sweden to improve the sales structure of our pharmaceutical products. Eisai will strive to accelerate the expansion of our business with a comprehensive view of all over the Europe, enhance satisfaction of patients and contribute to the improvement of benefits of more patients in Europe in the future.
Other news from the department business & finance

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

New compound that withstands extreme heat and electricity could lead to next-generation energy storage devices - Flexible polymers made with a new generation of the Nobel-winning “click chemistry” reaction find use in capacitors and other applications
A molecular switch for on-demand cargo release

Levitating rarities - Magnetic trapping of rare-earth ions may lead to a handy technology for their separation

Piecework at the nano assembly line - Fast computer control for molecular machines

Why Shouldn’t You Eat Rhubarb Leaves?
Bayer MaterialScience LLC appoints Dirk Schapeler CEO of Artificial Muscle, Inc.

Facility Monitoring Systems Ltd - Great Malvern, United Kingdom
Azelis Deutschland wins Bluestar award for Market Development for silicones and other specialities

Micro-engineered electrodes could cut battery manufacturing costs - "As 3D printers gain increasing resolution, sodium ion batteries could eventually outperform lithium ion ones"

Full focus on electrolysis - Sunfire spins off its fuel cell business, Sunfire Fuel Cells
